New research suggests that Escherichia coli Nissle 1917 (EcN) may be engineered with anticancer agents to treat cancerous tumors in mice. Researchers used EcN as a base for synthesizing Romidepsin (FK228), an FDA-approved drug with anti-tumor agents.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.